Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease - PubMed (original) (raw)
Review
Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease
Douglas L Feinstein. Diabetes Technol Ther. 2003.
Abstract
Activation of peroxisome proliferator-activated receptors (PPARs) mediates the insulin-sensitizing effects of thiazolidinediones used for treatment of type 2 diabetes, owing to changes in the transcription and expression of genes influencing carbohydrate and lipid metabolism. However, PPAR activation can have additional effects upon cellular physiology, including anti-proliferative and anti-inflammatory. These effects are observed in many cell types, including brain glial cells and blood lymphocytes, cells whose activation contributes to the initiation and progression of damage occurring in neurological diseases such as Alzheimer's disease (AD) and multiple sclerosis (MS). In view of the need for development of additional therapeutic options, several recent studies have tested the possibility that PPAR agonists would be neuroprotective in these diseases. This paper will summarize data from cell culture experiments and from studies in animal models, demonstrating that PPARgamma agonists can exert neuroprotective effects, thereby providing the basis for the design of clinical trials to test the safety and efficacy of thiazolidinediones in neuroinflammatory conditions such as AD and MS.
Similar articles
- Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT. Feinstein DL, et al. Ann Neurol. 2002 Jun;51(6):694-702. doi: 10.1002/ana.10206. Ann Neurol. 2002. PMID: 12112074 - Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients.
Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. Schmidt S, et al. J Leukoc Biol. 2004 Mar;75(3):478-85. doi: 10.1189/jlb.0803402. Epub 2003 Dec 4. J Leukoc Biol. 2004. PMID: 14657213 - Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents.
Kaundal RK, Sharma SS. Kaundal RK, et al. Drug News Perspect. 2010 May;23(4):241-56. doi: 10.1358/dnp.2010.23.4.1437710. Drug News Perspect. 2010. PMID: 20520853 Review. - Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development.
Kim MJ, Deplewski D, Ciletti N, Michel S, Reichert U, Rosenfield RL. Kim MJ, et al. Mol Genet Metab. 2001 Nov;74(3):362-9. doi: 10.1006/mgme.2001.3242. Mol Genet Metab. 2001. PMID: 11708867 - Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.
Grommes C, Landreth GE, Heneka MT. Grommes C, et al. Lancet Oncol. 2004 Jul;5(7):419-29. doi: 10.1016/S1470-2045(04)01509-8. Lancet Oncol. 2004. PMID: 15231248 Review.
Cited by
- Quantitative 3D histochemistry reveals region-specific amyloid-β reduction by the antidiabetic drug netoglitazone.
Catto F, Dadgar-Kiani E, Kirschenbaum D, Economides A, Reuss AM, Trevisan C, Caredio D, Mirzet D, Frick L, Weber-Stadlbauer U, Litvinov S, Koumoutsakos P, Hyung Lee J, Aguzzi A. Catto F, et al. bioRxiv [Preprint]. 2024 Aug 17:2024.08.15.608042. doi: 10.1101/2024.08.15.608042. bioRxiv. 2024. PMID: 39185170 Free PMC article. Preprint. - Therapeutic modulation of JAK-STAT, mTOR, and PPAR-γ signaling in neurological dysfunctions.
Kumar S, Mehan S, Narula AS. Kumar S, et al. J Mol Med (Berl). 2023 Feb;101(1-2):9-49. doi: 10.1007/s00109-022-02272-6. Epub 2022 Dec 7. J Mol Med (Berl). 2023. PMID: 36478124 Review. - Pharmacological Treatment for Neuroinflammation in Stress-Related Disorder.
Lee DH, Lee JY, Hong DY, Lee EC, Park SW, Lee YK, Oh JS. Lee DH, et al. Biomedicines. 2022 Oct 9;10(10):2518. doi: 10.3390/biomedicines10102518. Biomedicines. 2022. PMID: 36289780 Free PMC article. Review. - A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.
Collongues N, Becker G, Jolivel V, Ayme-Dietrich E, de Seze J, Binamé F, Patte-Mensah C, Monassier L, Mensah-Nyagan AG. Collongues N, et al. Neurol Ther. 2022 Sep;11(3):981-1042. doi: 10.1007/s40120-022-00363-7. Epub 2022 May 24. Neurol Ther. 2022. PMID: 35610531 Free PMC article. Review. - Bis(ethylmaltolato)oxidovanadium (IV) alleviates neuronal apoptosis through regulating peroxisome proliferator-activated receptor γ in a triple transgenic animal model of Alzheimer's disease.
He Z, Song J, Li X, Li X, Zhu H, Wu C, Xiao W, Du X, Ni J, Li N, Liu Q. He Z, et al. J Biol Inorg Chem. 2021 Aug;26(5):551-568. doi: 10.1007/s00775-021-01874-8. Epub 2021 Jul 8. J Biol Inorg Chem. 2021. PMID: 34240269
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources